Roelof Rongen - Net Worth and Insider Trading
Roelof Rongen Net Worth
The estimated net worth of Roelof Rongen is at least $266,871 dollars as of 2024-09-20. Roelof Rongen is the CEO of Matinas BioPharma Holdings Inc and owns about 70,788 shares of Matinas BioPharma Holdings Inc (MTNB) stock worth over $266,871. Details can be seen in Roelof Rongen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Roelof Rongen has not made any transactions after 2017-09-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Roelof Rongen
Roelof Rongen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Roelof Rongen owns 2 companies in total, including Matinas BioPharma Holdings Inc (MTNB) , and GRI Bio Inc (GRI) .
Click here to see the complete history of Roelof Rongen’s form 4 insider trades.
Insider Ownership Summary of Roelof Rongen
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
MTNB | Matinas BioPharma Holdings Inc | 2017-09-08 | director & Chief Executive Officer |
GRI | GRI Bio Inc | 2023-04-21 | director |
Roelof Rongen Latest Holdings Summary
Roelof Rongen currently owns a total of 1 stock. Roelof Rongen owns 70,788 shares of Matinas BioPharma Holdings Inc (MTNB) as of September 8, 2017, with a value of $266,871.
Latest Holdings of Roelof Rongen
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
MTNB | Matinas BioPharma Holdings Inc | 2017-09-08 | 70,788 | 3.77 | 266,871 |
Holding Weightings of Roelof Rongen
Roelof Rongen Form 4 Trading Tracker
According to the SEC Form 4 filings, Roelof Rongen has made a total of 0 transactions in Matinas BioPharma Holdings Inc (MTNB) over the past 5 years. The most-recent trade in Matinas BioPharma Holdings Inc is the acquisition of 100 shares on September 8, 2017, which cost Roelof Rongen around $6,800.
Insider Trading History of Roelof Rongen
- 1
Roelof Rongen Trading Performance
GuruFocus tracks the stock performance after each of Roelof Rongen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Roelof Rongen is 11.11%. GuruFocus also compares Roelof Rongen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Roelof Rongen within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Roelof Rongen's insider trading performs compared to the benchmark.
Roelof Rongen Ownership Network
Roelof Rongen Owned Company Details
What does Matinas BioPharma Holdings Inc do?
Who are the key executives at Matinas BioPharma Holdings Inc?
Roelof Rongen is the director & Chief Executive Officer of Matinas BioPharma Holdings Inc. Other key executives at Matinas BioPharma Holdings Inc include Chief Business Officer Thomas Hoover , director & Chief Executive Officer Jerome D Jabbour , and Chief Financial Officer Keith A Kucinski .
Matinas BioPharma Holdings Inc (MTNB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Matinas BioPharma Holdings Inc (MTNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Matinas BioPharma Holdings Inc (MTNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Matinas BioPharma Holdings Inc (MTNB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Matinas BioPharma Holdings Inc Insider Transactions
Roelof Rongen Mailing Address
Above is the net worth, insider trading, and ownership report for Roelof Rongen. You might contact Roelof Rongen via mailing address: C/o Matinas Biopharma Holdings, Inc., 1545 Route 206 South, Suite 302, Bedminster Nj 07921.